These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 14218606)

  • 21. [Biology of attenuated mumps, rubella, measles and rabies viruses. Comparative considerations on the methods of attenuation of their virulence].
    Ciaccio G
    Riv Biol; 1970; 63(1):87-129. PubMed ID: 4996066
    [No Abstract]   [Full Text] [Related]  

  • 22. Studies on the development of a live attenuated mumps virus vaccine. II. Development and evaluation of the live "Hoshino" mumps vaccine.
    Makino S; Yamane Y; Sasaki K; Nagashima T; Higashihara M
    Kitasato Arch Exp Med; 1976 Jun; 49(1-2):53-62. PubMed ID: 1025341
    [No Abstract]   [Full Text] [Related]  

  • 23. THE INTERACTION OF NEWCASTLE DISEASE VIRUS AND NEUTRALIZING ANTIBODY.
    GRANOFF A
    Virology; 1965 Jan; 25():38-47. PubMed ID: 14277083
    [No Abstract]   [Full Text] [Related]  

  • 24. Studies on the development of a live attenuated mumps virus vaccine. I. Attenuation of the Hoshino "wild" strain of mumps virus.
    Sasaki K; Higashihara M; Inoue K; Igarashi Y; Makino S
    Kitasato Arch Exp Med; 1976 Jun; 49(1-2):43-52. PubMed ID: 828947
    [No Abstract]   [Full Text] [Related]  

  • 25. [Anti-mumps vaccination with a live attenuated vaccine in a children's collective].
    Drouhet V; Celers J; Minvielle A
    Bull Acad Natl Med; 1970 Jun; 154(23):570-6. PubMed ID: 4922864
    [No Abstract]   [Full Text] [Related]  

  • 26. Studies on live attenuated mumps vaccine. II. Follow-up study on the efficacy of Biken Vaccine.
    Isomura S; Ozaki T; Morishima T; Nagayoshi S; An S
    Biken J; 1976 Sep; 19(3):115-8. PubMed ID: 1016214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a focus reduction neutralization test (FRNT) for detection of mumps virus neutralizing antibodies.
    Vaidya SR; Brown DW; Jin L; Samuel D; Andrews N; Brown KE
    J Virol Methods; 2010 Jan; 163(1):153-6. PubMed ID: 19761798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Virus strain specific serum neutralizing antibodies in children and adolescents immunized with a Russian mumps vaccine].
    Otrashevskaia EV; Krasil'nikov IV; Ignat'ev GM
    Vopr Virusol; 2010; 55(6):15-9. PubMed ID: 21381334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a live attenuated mumps vaccine (Jeryl Lynn). With observations on the optimal time for testing serologic response.
    Brunell PA; Brickman A; Steinberg S
    Am J Dis Child; 1969 Sep; 118(3):435-40. PubMed ID: 5812074
    [No Abstract]   [Full Text] [Related]  

  • 30. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transmission of live, attenuated mumps virus to the human placenta.
    Yamauchi T; Wilson C; Geme JW
    N Engl J Med; 1974 Mar; 290(13):710-2. PubMed ID: 4813744
    [No Abstract]   [Full Text] [Related]  

  • 32. STUDIES ON THE LOW EGG PASSAGE FLURY STRAIN OF MODIFIED LIVE RABIES VIRUS PRODUCED IN EMBRYONATING CHICKEN EGGS AND TISSUE CULTURE.
    DEAN DJ; EVANS WM; THOMPSON WR
    Am J Vet Res; 1964 May; 25():756-63. PubMed ID: 14141518
    [No Abstract]   [Full Text] [Related]  

  • 33. Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays.
    Mauldin J; Carbone K; Hsu H; Yolken R; Rubin S
    J Clin Microbiol; 2005 Sep; 43(9):4847-51. PubMed ID: 16145156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and biological properties of a new live attenuated mumps vaccine.
    Saika S; Kidokoro M; Kubonoya H; Ito K; Ohkawa T; Aoki A; Nagata N; Suzuki K
    Comp Immunol Microbiol Infect Dis; 2006; 29(2-3):89-99. PubMed ID: 16647119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Live attenuated mumps virus vaccine. 1. Vaccine development.
    Buynak EB; Hilleman MR
    Proc Soc Exp Biol Med; 1966 Dec; 123(3):768-75. PubMed ID: 4163620
    [No Abstract]   [Full Text] [Related]  

  • 36. Enzyme immunoassay of mumps virus in cell culture with peroxidase-labelled virus specific monoclonal antibodies and its application for determination of antibodies.
    van Tiel FH; Kraaijeveld CA; Baller J; Harmsen T; Oosterlaken TA; Snippe H
    J Virol Methods; 1988 Oct; 22(1):99-108. PubMed ID: 3058739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of a novel formalin-inactivated and alum-adjuvanted candidate subunit vaccine for mumps.
    Liang Y; Ma S; Yang Z; Liu L; Wang L; Wang J; Jiang L; Shi C; Dong C; Li Q
    Vaccine; 2008 Aug; 26(33):4276-83. PubMed ID: 18597904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Material for a study of immunity against mumps by the neutralization reaction in tissue cultures.
    Galko NV
    J Hyg Epidemiol Microbiol Immunol; 1965; 9(4):500-9. PubMed ID: 5893862
    [No Abstract]   [Full Text] [Related]  

  • 39. Eliciting neutralizing antibodies against the membrane proximal external region of HIV-1 Env by chimeric live attenuated influenza A virus vaccines.
    Zang Y; Du D; Li N; Su W; Liu X; Zhang Y; Nie J; Wang Y; Kong W; Jiang C
    Vaccine; 2015 Jul; 33(32):3859-64. PubMed ID: 26126669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TISSUE-CULTURE SYSTEMS WITH NEWCASTLE DISEASE VIRUS AND RELATIONSHIP OF ANTIGENICITY TO IMMUNOGENICITY AMONG STRAINS.
    BANKOWSKI RA; KINJO J
    Avian Dis; 1965 Feb; 9(1):157-70. PubMed ID: 14253987
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.